Baxter International Inc's Corporate Customers have recorded an advance in their cost of revenue by 8.79 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -5.19 %. During the corresponding time, Baxter International Inc recorded a revenue increase by 2.9 % year on year, sequentially revenue fell by -9.18 %. While revenue at the Baxter International Inc 's corporate clients recorded rose by 6.68 % year on year, sequentially revenue fell by -4.41 %.
Baxter International Inc's Customers have recorded an advance in their cost of revenue by 8.79 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -5.19 %, for the same period Baxter International Inc recorded revenue increase by 2.9 % year on year, sequentially revenue fell by -9.18 %.
Baxter International Inc's Comment on Sales, Marketing and Customers
The company provides connected care devices and software for the healthcare sector, enabling digital connectivity, communication, and data analysis to support patient outcomes. Its connected care portfolio comprises smart bed systems, infusion pumps, patient monitoring and diagnostic technologies, respiratory health devices, and advanced surgical equipment. The company’s core therapy products include pharmaceuticals and consumable medical products that address essential needs across the continuum of care. It focuses on higher-growth markets and emphasizes innovation, portfolio optimization, and operational simplification to improve responsiveness, expand patient access, and accelerate growth.
Baxter Expands Surgical Innovations with Room Temperature Stable Hemopatch, Amidst Revenue Challenges for Corporate Clients Baxter International Inc. Introduces Room Temperature Stable Hemopatch Hemostat: Innovations in Surgical Practice Amidst Corporate Revenue Fluctuations In a bold move to enhance surgical outcomes, Baxter International Inc. (NYSE: BAX), a globally recognized leader in surgical innovation, has unveiled the Hemopatch Sealing Hemostat at a symposium in Vienna, Austria. This groundbreaking product is designed for immediate deployment in the operating room, optimizing accessibility while providing surgeons with an effective solution for achieving hemorrhage control and preventing fluid leaks...
The Future of Healthcare Communication: Baxter s Transformative Leap with Voalte Linq In an era where efficient communication can dramatically influence patient care outcomes, Baxter International Inc. (NYSE:BAX), a leading force in the global medical technology landscape, has taken a pioneering step at the forefront of healthcare innovation, unveiling its groundbreaking Voalte Linq device during the 2025 HIMSS Global Healthcare Conference in Las Vegas. This cutting-edge, voice-activated technology promises to revolutionize how healthcare teams communicate, ultimately enhancing care delivery in hospitals and medical institutions across the nation. A New Dawn in Voice-Activated Technology Voalte Linq, a ligh...
In a remarkable showcase of growth within its pharmaceuticals division, Baxter International Inc. (NYSE:BAX) recently announced the launch of five new injectable products in the U.S. This development adds to the five launches introduced in April, culminating in a total of ten new injectable products this year. Baxter has established itself as a leader in the injectables sector, emphasizing its commitment to delivering differentiated products that meet the evolving needs of healthcare providers and patients alike.The importance of these product launches cannot be understated. Baxter s strategy to expand its pharmaceuticals portfolio showcases an intent to address healthcare challenges through innovation. By i...
Baxter International Reports Positive Third-Quarter Results While Navigating Strategic Transformation In a notable demonstration of resilience and strategic focus, Baxter International Inc. (NYSE: BAX), a leading player in the global medtech sector, disclosed its third-quarter results for 2024, reporting a performance that reflects ongoing efforts to transform the company. During a recent release, Jos (Joe) E. Almeida, the company s chair, president, and chief executive officer, highlighted the positive trajectory Baxter has maintained as it endeavors to execute its comprehensive transformation strategy.The quarter’s performance was buoyed by a strong operational framework as Baxter progresses towards a pa...
In the wake of Hurricane Helene s severe impact on the North Cove facility in Marion, North Carolina, Baxter International Inc. (NYSE:BAX), a global leader in medical technology, has provided a comprehensive update regarding both the operational challenges posed by flooding and the company s financial health. The storm, which brought unprecedented rainfall and extensive flooding to Western North Carolina, has resulted in the temporary closure of Baxter s North Cove production facility. In response, the company emphasizes its commitment to supporting the affected community through coordinated relief efforts with local, state, and federal agencies.The repercussions of Hurricane Helene are set against the backd...
In its recently published 2023 Corporate Responsibility Report, Baxter International Inc. reinforces its unwavering dedication to making a lasting impact on global healthcare while demonstrating transparency in environmental, social, and governance practices. Despite confronting challenges posed by the ongoing economic landscape, Baxter remains steadfast in its mission to conduct business ethically and contribute to the well-being of its stakeholders.Financial results in Q1 revealed a remarkable reduction of 8.8% in costs of revenue for Baxter s corporate clients, marking an impressive achievement compared to the previous year. Sequentially, a significant trimming of 38.81% in costs of revenue further unders...
Baxter International Announces Ambitious New Venture Amidst Revenue ChallengesIn an exciting development, Baxter International Inc. (NYSE:BAX), a global leader in medical technology, announced the mission and logo for its newly proposed kidney care and acute therapies company, Vantive. Amidst challenging financial metrics for Q1, this strategic venture is part of Baxter’s ongoing efforts to reshape its business and address pressing market needs. Vantive: A New Dawn in Kidney CareAccording to the announcement, the mission of Vantive, “Extending Lives, Expanding Possibilities,” encapsulates the company’s commitment to developing critical therapies for acute and chronic kidney diseases. This larger pur...
Baxter International Inc’s Comment on Sales, Marketing and Customers
The company provides connected care devices and software for the healthcare sector, enabling digital connectivity, communication, and data analysis to support patient outcomes. Its connected care portfolio comprises smart bed systems, infusion pumps, patient monitoring and diagnostic technologies, respiratory health devices, and advanced surgical equipment. The company’s core therapy products include pharmaceuticals and consumable medical products that address essential needs across the continuum of care. It focuses on higher-growth markets and emphasizes innovation, portfolio optimization, and operational simplification to improve responsiveness, expand patient access, and accelerate growth.
Sources:
Baxter International Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Baxter International Inc’s corporate clients.
For your research, we’ve provided 9 tables on Baxter International Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
0.19 %
102.15 %